Latest News

February 2020: Dr Olga Gandelman joins the Board of DiagNodus

January 2019: The multicentre clinical study of the use of DiagNodus approach for CRC detection produces impressive results

May 2018: Sample collection for the multicentre clinical study of the use of DiagNodus approach for CRC detection successfully completed

December 2017: The clinical study of the use of DiagNodus approach for CRC detection made multicentre (Yeovil District Hospital and Southend University Hospital joined the study)




DiagNodus has designed and patented methods for non-invasive collection and analysis of samples indicative of the state of the human bowel. The technology is based upon disease biomarker detection. The approach addresses a range of diagnostic, screening and monitoring applications within the field of colorectal disease, in particular targeting inflammatory bowel disease (IBD) and colorectal cancer (CRC). The company has already established analytical laboratory techniques employing quantitative immunochemical determination of IBD markers and is now developing point of care test kits, which will be made as disposable single-application units designed for rapid testing.

The technology devised by DiagNodus allows non-invasive determination of bowel inflammation activity, permitting IBD diagnosis, monitoring and therapy efficiency assessment. It will also represent a paradigm shift in CRC screening and it is expected over time to replace the existing faecal occult blood test (FOBT), immunochemical version of which (FIT) is currently replacing the old FOBT. FIT relies on the detection of traces of blood in stool, but its sensitivity remains limited. Moreoever, stool collection is unpleasant and often inconvenient, and screening test uptake is negatively affected by these factors. The patient-friendly approach developed by DiagNodus will use biomarkers providing a more reliable indication of the presence of CRC.

DiagNodus technology offers the following advantages for colorectal disease diagnosis, monitoring and screening:

  • Inexpensive
  • Non-invasive
  • Self applied
  • Rapid / Point of Care
  • Sensitivity and specificity expected to exceed that of existing methods




© DiagNodus 2020. All rights reserved. Terms of Use Policy. Privacy Policy
DiagNodus Ltd Registered in England number: 7600875 VAT Number: 121522366
Registered Office: 280 Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT